1.22% -0.0079

Biora Therapeutics Inc (BIOR)

Biora Therapeutics Inc Borsa (BIOR) Ultime notizie

Biora Therapeutics Inc (BIOR)

Biora Therapeutics Inc Borsa (BIOR) Ultime notizie

Biora Therapeutics secures additional $4 million financing - Investing.com

Biora Therapeutics Achieves ISO 13485 Certification - GlobeNewswire

Biora Therapeutics Achieves ISO 13485 Certification - StockTitan

A History of Outperforming Analyst Forecasts and Beating the Odds: Biora Therapeutics Inc (BIOR) - SETE News

Biora Therapeutics Announces Positive Nasdaq Listing Decision - GlobeNewswire

Biora Therapeutics Announces Positive Nasdaq Listing Decision - StockTitan

Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire

Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - The Bakersfield Californian

Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Biora Therapeutics secures new financial agreements - Investing.com India

Biora Therapeutics secures new financial agreements - Investing.com

BIOR: Second Quarter Results - Yahoo Finance

Biora Therapeutics, Inc. (NASDAQ:BIOR) Forecasted to Post Q3 2024 Earnings of ($0.42) Per Share - Defense World

BIOR’s Stock Woes: Down -20.37% in 6 Months, Down -20.37% in Just 5 Days - The InvestChronicle

Biora Therapeutics Second Quarter 2024 Earnings: EPS: US$0.18 (vs US$1.47 loss in 2Q 2023) - Yahoo Finance

Biora Therapeutics (NASDAQ:BIOR) Receives “Buy” Rating from HC Wainwright - Defense World

Biora Therapeutics, Inc. (NASDAQ:BIOR) Q2 2024 Earnings Call Transcript - Insider Monkey

Biora Therapeutics maintains stock target after strong Q2 results By Investing.com - Investing.com UK

Earnings call: Biora Therapeutics reports progress on BT-600 and BioJet platforms - Investing.com

Biora Therapeutics Inc (BIOR) Q2 2024 Earnings Call Transcript H - GuruFocus.com

BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024 - MSN

BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024 - InvestorPlace

Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript - Seeking Alpha

Biora Therapeutics Restructures Debt and Issues New Securities - TipRanks

Biora Therapeutics Announces Funding Agreement with Existing Investors - GlobeNewswire

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - GlobeNewswire

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - StockTitan

Biora Therapeutics Announces Funding Agreement with Existing Investors - StockTitan

Biora Therapeutics (BIOR) Set to Announce Quarterly Earnings on Monday - Defense World

Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update - GlobeNewswire

Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update - Yahoo Finance

Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference - GlobeNewswire

Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference - StockTitan

HC Wainwright Reiterates Buy Rating for Biora Therapeutics (NASDAQ:BIOR) - Defense World

Biora reports promising BT-600 ulcerative colitis trial results - Investing.com

Anchoring Your Portfolio: Is BIOR Stock a Safe Harbor? - The InvestChronicle

Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event - GlobeNewswire

Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as ... - The Bakersfield Californian

Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event - StockTitan

Biora Therapeutics (NASDAQ:BIOR) Stock Price Up 2.3% - Defense World

Biora Therapeutics Announces Positive Clinical Trial Results for BT-600 - Technology Networks

Biora Therapeutics to Host Virtual KOL Event on NaviCap™ - GlobeNewswire

Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024 - Yahoo Finance

BIOR: BT-600 Topline - Yahoo Finance

Market Insights: Biora Therapeutics Inc (BIOR)’s Notable Gain of 3.25, Closing at 0.63 - The Dwinnex

A year in review: Biora Therapeutics Inc (BIOR)’s performance in the last year - US Post News

Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Quantisnow

BIORBiora Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Biora Therapeutics Reports Promising BT-600 Trial Results - TipRanks

Biora Therapeutics Announces Positive Clinical Trial Results for BT-600 - GlobeNewswire

Biora Therapeutics To Present On The BioJet Systemic Oral Delivery Platform At The Next Gen Peptide Formulation ... - Quantisnow

Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Quantisnow

Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist - Quantisnow

Biora Therapeutics Announces Closing of $8 Million Registered Direct Offering of Common Stock and Warrants Priced ... - Quantisnow

Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting ... - Quantisnow

Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets - Quantisnow

GLP-1 Agonists Market to Grow Rapidly by 2034, Predicts - GlobeNewswire

Biora Therapeutics (NASDAQ:BIOR) Shares Up 1.5% - Defense World

Biora Therapeutics Inc (BIOR)'s results reveal risk – US Post News - US Post News

Simile a BIOR